🇫🇷Emmanuelle
Charpentier

Emmanuelle Charpentier grew up in the suburbs of Paris and decided she wanted to be a scientist at the age of twelve, after visiting the Institut Pasteur — the legendary research institute founded by Louis Pasteur — and resolving that one day she would work there. She fulfilled that ambition before she was thirty, completing her PhD in microbiology and biochemistry at the Pasteur in 1995. Then she left France for a scientific odyssey that would take her through New York, Memphis, Vienna, Umea, and ultimately to Berlin, working in six countries across twenty-five years, never staying anywhere long enough to settle, following the science wherever it led. It led, eventually, to a discovery that changed the history of biology.

Charpentier's scientific focus was on how bacteria regulate gene expression and defend themselves against infection — questions that sound narrow but turn out to be connected to almost everything in molecular biology. In the late 2000s, working in Vienna and then at Umea University in Sweden, she began investigating a curious small RNA molecule associated with the CRISPR system in the bacterium Streptococcus pyogenes — the bacterium responsible for strep throat. The CRISPR system was known: bacteria used it to store fragments of viral DNA and recognize returning viruses. What was less understood was the molecular machinery by which the system actually cut viral DNA when a returning pathogen was detected.

In 2011, Charpentier published a paper identifying a previously unknown RNA molecule she called tracrRNA — trans-activating CRISPR RNA — and demonstrating that it was essential to the function of the Cas9 protein, the molecular scissors at the heart of the CRISPR defense system. Without tracrRNA, Cas9 could not find its target or make its cut. This was a fundamental discovery about bacterial biology. Its implications for biotechnology were not yet apparent — until that same year, at a scientific conference in Puerto Rico, she met Jennifer Doudna.

The collaboration was swift and transatlantic. Charpentier, working in Sweden, and Doudna, in Berkeley, spent a year figuring out how to harness the CRISPR-Cas9 system as a programmable tool. The key insight — largely contributed by Charpentier's understanding of the RNA machinery — was that the tracrRNA and the guide RNA could be fused into a single synthetic RNA molecule that could be designed to direct Cas9 to any DNA sequence in any genome. The 2012 paper in Science demonstrated this conclusively: CRISPR-Cas9 was a universal, programmable gene editor. The world of biology divided into before and after.

Charpentier's trajectory after 2012 reflected her characteristically peripatetic independence. She moved from Sweden to the Helmholtz Centre for Infection Research in Germany, then founded and directs the Max Planck Unit for the Science of Pathogens in Berlin, one of the most prestigious positions in European science. She has been notably private about her personal life and deliberate in her public statements about CRISPR's ethical dimensions, consistently arguing that scientific power demands proportionate governance. In 2020, she and Doudna received the Nobel Prize in Chemistry — awarded, the committee noted, for a tool that had "rewritten the code of life." Charpentier learned of the prize in her Berlin apartment, alone. She called it one of the most meaningful moments of her life.